南财智讯6月24日电,诺诚健华公告,公司执行董事、董事会主席、行政总裁崔霁松拟通过集中竞价方式减持不超过20.625万股A股股份,即不超过公司总股本的0.0117%;执行董事、血液瘤医学研究和临床开发高级副总裁赵仁滨拟通过集中竞价方式减持不超过5万股A股股份,即不超过公司总股本的0.0028%;首席技术官陈向阳拟通过集中竞价方式减持不超过6.25万股A股股份,即不超过公司总股本的0.0035%。...
Source Link南财智讯6月24日电,诺诚健华公告,公司执行董事、董事会主席、行政总裁崔霁松拟通过集中竞价方式减持不超过20.625万股A股股份,即不超过公司总股本的0.0117%;执行董事、血液瘤医学研究和临床开发高级副总裁赵仁滨拟通过集中竞价方式减持不超过5万股A股股份,即不超过公司总股本的0.0028%;首席技术官陈向阳拟通过集中竞价方式减持不超过6.25万股A股股份,即不超过公司总股本的0.0035%。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.